{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:27:22Z","timestamp":1785472042829,"version":"3.56.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.amjcard.2021.04.042","type":"journal-article","created":{"date-parts":[[2021,6,20]],"date-time":"2021-06-20T16:10:32Z","timestamp":1624205432000},"page":"138-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure"],"prefix":"10.1016","volume":"152","author":[{"given":"Andrew P.","family":"Ambrosy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Court","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"McDonagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1471-7016","authenticated-orcid":false,"given":"John G.F.","family":"Cleland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2021.04.042_bib0001","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/ajh.25564","article-title":"A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial","volume":"94","author":"Auerbach","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0002","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfaa011","article-title":"Safety and efficacy of iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial","volume":"36","author":"Bhandari","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0003","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/ehjqcco\/qcz010","article-title":"Go AS; RBC Heart Investigators. Incident anaemia in older adults with heart failure: rate, aetiology, and association with outcomes","volume":"5","author":"Ambrosy","year":"2019","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0004","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijcard.2020.03.020","article-title":"Go AS; RBC Heart Investigators\/PACTTE Consortium. A reduced transferrin saturation is independently associated with excess morbidity and mortality in older adults with heart failure and incident anemia","volume":"309","author":"Ambrosy","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0005","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/jamacardio.2016.1161","article-title":"Prevalence and outcomes of anemia and hematinic deficiencies in patients with chronic heart failure","volume":"1","author":"Cleland","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0006","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s00392-016-1073-y","article-title":"Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: The PrEP registry","volume":"106","author":"von Haehling","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0007","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijcard.2015.11.178","article-title":"The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the studies investigating co-morbidities aggravating heart failure","volume":"205","author":"Ebner","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0008","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijcard.2014.03.169","article-title":"Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study","volume":"174","author":"Enjuanes","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0009","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jacc.2008.04.061","article-title":"Anemia and mortality in heart failure patients: A systematic review and meta-analysis","volume":"52","author":"Groenveld","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0010","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0011","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0012","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.027497","article-title":"Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency","volume":"136","author":"van Veldhuisen","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0013","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0014","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0015","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0016","first-page":"1342","article-title":"2017 comprehensive update of the Canadian Cardiovascular Society Guidelines for the management of heart failure","volume":"33","author":"Ezekowitz","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0017","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.hlc.2018.06.1042","article-title":"National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: guidelines for the prevention, detection, and management of heart failure in Australia 2018","volume":"27","author":"Atherton","year":"2018","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0018","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1161\/CIRCULATIONAHA.118.038516","article-title":"Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency","volume":"139","author":"Charles-Edwards","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0019","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ejhf.823","article-title":"Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis","volume":"20","author":"Anker","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0020","doi-asserted-by":"crossref","DOI":"10.1007\/s00392-021-01837-8","article-title":"Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials","author":"Graham","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0021","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/17474086.2020.1709437","article-title":"Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia","volume":"13","author":"Pollock","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0022","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.jacc.2018.03.448","article-title":"High-dose ferric carboxymaltose in patients with HFrEF induces significant hypophosphatemia","volume":"71","author":"St\u00f6hr","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0023","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0024","doi-asserted-by":"crossref","DOI":"10.1002\/ygh2.415","article-title":"Hypophosphataemia after intravenous iron therapy with ferric carboxymaltose \u2013 real world experience from a tertiary centre in the UK","author":"Fragkos","year":"2020","journal-title":"GastroHep"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0025","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MNH.0000000000000329","article-title":"Iron-induced hypophosphatemia: an emerging complication","volume":"26","author":"Zoller","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0026","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.amjcard.2021.04.042_bib0027","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ejheart.2005.04.001","article-title":"Do discharge codes underestimate hospitalisation due to heart failure? Validation study of hospital discharge coding for heart failure","volume":"7","author":"Khand","year":"2005","journal-title":"Eur J Heart Fail"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914921004227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914921004227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:05:55Z","timestamp":1762077955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914921004227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":27,"alternative-id":["S0002914921004227"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2021.04.042","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2021.04.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}